FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120292172> ?p ?o ?g. }

• W3120292172 abstract "Abstract Research question There is no widely accepted grading system for IPF disease severity, although physiologic impairment based on pulmonary function testing is frequently employed. We sought to describe clinical and functional characteristics as well as outcomes of patients with severe physiologic impairment. Patients and methods IPF patients with severe physiologic impairment defined by FVC ≤ 50% and/or DLco ≤ 30% predicted evaluated in the Inova Advanced Lung Disease Program between 2011 and 2019 were included. Demographic, physiologic, functional treatment and outcome data were collated. Results There were 531 patients with IPF evaluated of whom 242 (46%) had severe physiologic impairment. Mean age was 72 ± 8 years; baseline FVC was 53 ± 17% and DL CO 28 ± 9% of predicted. The mean 6 min walks test (6MWT) distance was 304 ± 121 m with 59% of the patients requiring supplemental oxygen ( $${text{6MWT}}_{{{text{O}}_{{2}} }}$$ <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML> <mml:msub> <mml:mtext>6MWT</mml:mtext> <mml:msub> <mml:mtext>O</mml:mtext> <mml:mn>2</mml:mn> </mml:msub> </mml:msub> </mml:math> group). There was a poor correlation between the 6MWT distance and both FVC% and DLco%. Patients in the 6MWT RA group had a better transplant-free survival than the $${text{6MWT}}_{{{text{O}}_{{2}} }}$$ <mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML> <mml:msub> <mml:mtext>6MWT</mml:mtext> <mml:msub> <mml:mtext>O</mml:mtext> <mml:mn>2</mml:mn> </mml:msub> </mml:msub> </mml:math> group (p = 0.002). Patients managed before October 2014 and not receiving antifibrotic therapy had worse outcomes with reduced transplant-free survival compared with patients presenting after this date who did receive antifibrotic therapy (n = 113) (log rank p < 0.0001). Conclusion IPF patients often present with severe physiologic impairment which may be poorly correlated with their functional status. Assessment of IPF disease severity should not be based on physiologic impairment alone, but should also encompass functional status as well as need for supplemental oxygen. Antifibrotic therapy in patients with severe physiologic impairment is associated with improved outcomes." @default.
• W3120292172 created "2021-01-18" @default.
• W3120292172 creator A5023272614 @default.
• W3120292172 creator A5029502671 @default.
• W3120292172 creator A5030294739 @default.
• W3120292172 creator A5036739792 @default.
• W3120292172 creator A5042476197 @default.
• W3120292172 creator A5046325850 @default.
• W3120292172 creator A5050847412 @default.
• W3120292172 creator A5060493749 @default.
• W3120292172 creator A5071420068 @default.
• W3120292172 creator A5075216176 @default.
• W3120292172 date "2021-01-06" @default.
• W3120292172 modified "2023-09-26" @default.
• W3120292172 title "Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes" @default.
• W3120292172 cites W2004697839 @default.
• W3120292172 cites W2028558343 @default.
• W3120292172 cites W2057292199 @default.
• W3120292172 cites W2058234974 @default.
• W3120292172 cites W2069724928 @default.
• W3120292172 cites W2108678383 @default.
• W3120292172 cites W2117488044 @default.
• W3120292172 cites W2118894860 @default.
• W3120292172 cites W2123137799 @default.
• W3120292172 cites W2138871107 @default.
• W3120292172 cites W2161625871 @default.
• W3120292172 cites W2167383172 @default.
• W3120292172 cites W2168666423 @default.
• W3120292172 cites W2599075603 @default.
• W3120292172 cites W2750993488 @default.
• W3120292172 cites W2810699055 @default.
• W3120292172 cites W2889197569 @default.
• W3120292172 cites W2939662940 @default.
• W3120292172 cites W2941015552 @default.
• W3120292172 cites W3000956463 @default.
• W3120292172 cites W3007993053 @default.
• W3120292172 cites W3012614740 @default.
• W3120292172 cites W3016432216 @default.
• W3120292172 cites W3022958008 @default.
• W3120292172 cites W4233968038 @default.
• W3120292172 doi "https://doi.org/10.1186/s12931-020-01600-z" @default.
• W3120292172 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7788925" @default.
• W3120292172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33407450" @default.
• W3120292172 hasPublicationYear "2021" @default.
• W3120292172 type Work @default.
• W3120292172 sameAs 3120292172 @default.
• W3120292172 citedByCount "6" @default.
• W3120292172 countsByYear W31202921722021 @default.
• W3120292172 countsByYear W31202921722022 @default.
• W3120292172 countsByYear W31202921722023 @default.
• W3120292172 crossrefType "journal-article" @default.
• W3120292172 hasAuthorship W3120292172A5023272614 @default.
• W3120292172 hasAuthorship W3120292172A5029502671 @default.
• W3120292172 hasAuthorship W3120292172A5030294739 @default.
• W3120292172 hasAuthorship W3120292172A5036739792 @default.
• W3120292172 hasAuthorship W3120292172A5042476197 @default.
• W3120292172 hasAuthorship W3120292172A5046325850 @default.
• W3120292172 hasAuthorship W3120292172A5050847412 @default.
• W3120292172 hasAuthorship W3120292172A5060493749 @default.
• W3120292172 hasAuthorship W3120292172A5071420068 @default.
• W3120292172 hasAuthorship W3120292172A5075216176 @default.
• W3120292172 hasBestOaLocation W31202921721 @default.
• W3120292172 hasConcept C11413529 @default.
• W3120292172 hasConcept C117220453 @default.
• W3120292172 hasConcept C126322002 @default.
• W3120292172 hasConcept C16020263 @default.
• W3120292172 hasConcept C165637977 @default.
• W3120292172 hasConcept C2524010 @default.
• W3120292172 hasConcept C2777714996 @default.
• W3120292172 hasConcept C2778341716 @default.
• W3120292172 hasConcept C3018587741 @default.
• W3120292172 hasConcept C33923547 @default.
• W3120292172 hasConcept C71924100 @default.
• W3120292172 hasConcept C75603125 @default.
• W3120292172 hasConceptScore W3120292172C11413529 @default.
• W3120292172 hasConceptScore W3120292172C117220453 @default.
• W3120292172 hasConceptScore W3120292172C126322002 @default.
• W3120292172 hasConceptScore W3120292172C16020263 @default.
• W3120292172 hasConceptScore W3120292172C165637977 @default.
• W3120292172 hasConceptScore W3120292172C2524010 @default.
• W3120292172 hasConceptScore W3120292172C2777714996 @default.
• W3120292172 hasConceptScore W3120292172C2778341716 @default.
• W3120292172 hasConceptScore W3120292172C3018587741 @default.
• W3120292172 hasConceptScore W3120292172C33923547 @default.
• W3120292172 hasConceptScore W3120292172C71924100 @default.
• W3120292172 hasConceptScore W3120292172C75603125 @default.
• W3120292172 hasFunder F4320314924 @default.
• W3120292172 hasFunder F4320326049 @default.
• W3120292172 hasIssue "1" @default.
• W3120292172 hasLocation W31202921721 @default.
• W3120292172 hasLocation W31202921722 @default.
• W3120292172 hasLocation W31202921723 @default.
• W3120292172 hasLocation W31202921724 @default.
• W3120292172 hasOpenAccess W3120292172 @default.
• W3120292172 hasPrimaryLocation W31202921721 @default.
• W3120292172 hasRelatedWork W2141162061 @default.
• W3120292172 hasRelatedWork W2340104373 @default.
• W3120292172 hasRelatedWork W2552267583 @default.
• W3120292172 hasRelatedWork W2555155415 @default.
• W3120292172 hasRelatedWork W2556745572 @default.

• next